Other active comparator

Cyproterone ethinylestradiol

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

OTHER_ACTIVE_cyproterone_ethinylestradiol

Mechanism: Any other active drug or procedure randomized against a node of interest
Trials: 1
Participants in these arms: 35

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Polycystic ovary syndrome	Nausea	longest follow-up	Placebo	HR 0.20 (0.00 to 3.83)	0.94
Polycystic ovary syndrome	Vomiting	longest follow-up	Placebo	HR 0.21 (0.00 to 4.39)	0.95
Polycystic ovary syndrome	Diarrhea	longest follow-up	Placebo	HR 0.14 (0.00 to 2.35)	0.96
Polycystic ovary syndrome	Regular menstrual cycles	weeks 12 to 52 (target week 26)	Standard care or no added treatment	OR 1.76 (0.19 to 15.44)	0.53

Trials

NCT03151005
Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients
2017 · 70 randomized · 12 weeks

Cyproterone ethinylestradiol

Related

Effects across outcomes

Trials